The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

Meyerlustenberger Lachenal Ltd

RUE DU RHONE 65, PO BOX 3199, 1211 GENEVE 3, SWITZERLAND
Tel:
Work +41 22 737 10 00
Fax:
Fax +41 22 737 10 01
Email:
Web:
www.mll-legal.com
Meyerlustenberger Lachenal Ltd, Nicolas P. Didisheim, Geneva, SWITZERLAND

Nicolas P. Didisheim

Tel:
Work +41 22 737 10 00
Email:
Meyerlustenberger Lachenal Ltd

Work Department

Tax Law | Arbitration and Litigation | Private Clients

Position

Nicolas Didisheim is a senior partner in the private clients group in Geneva. His activities focus on advising, assisting and litigating for private clients and asset managers in matters involving asset management, cross-border issues, compliance, estate and trusts with complex tax issues. He devotes part of his time to philanthropic activities.
Nicolas Didisheim is a board member of various charitable organizations active in the medical or social fields. He advises the International Red Cross Committee (ICRC) in matters relating to fund-raising. Since 2015, Nicolas Didsheim is a member of the board of the Holding Benjamin and Edmond de Rothschild.

Career

Partner with Meyerlustenberger Lachenal (since 2001), Partner with a well renowned firm in Geneva (1996–2001), Legal counsel and head of compliance, Banque Privée Edmond de Rothschild (1993–2001), Senior associate with a well renowned firm in Geneva and Zurich (1987–1993), Admitted to the bar of Connecticut (1987), Admitted to the bar of New York (1987), Associate with Carrey & Langlois in Guernsey (1986), Professor’s assistant in tax law at the University of Geneva (1985–1986), Intern at Lloyd’s Bank International Plc (1985), Admitted to the bar in Switzerland (1985), Junior associate with well renowned firms in Geneva and Berne (1983–1985)

Languages

English, French, German

Member

Fédération suisse des Avocats (FSA), Ordre des Avocats de Genève (ODA), The Society of Trust and Estate Practitioners (STEP), Association genevoise du droit des affaires (AGDA)

Education

New York University School of Law, LL.M. (1987), University of Geneva, lic. iur. (1982)

Back to index

Legal Developments in Switzerland

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to
  • Ordinance on Integrity and Transparency in the Therapeutic Products Sector has been adopted

    Click here for more information.
  • Bär & Karrer Advises B3i in its Current Equity Funding Round

    Industry-led InsurTech B3i Services AG successfully raised additional funds from current shareholders and new investors to further develop and grow its blockchain-based insurance transaction platform. B3i was founded in October 2016 as an insurance industry consortium which then formed B3i Services AG as an independent company. The shareholder group includes some of the world's largest insurers and reinsurers from across Europe, the Americas, and Asia. B3i intends to further expand its shareholder base over the next several months.
  • Bär & Karrer Continues to Grow Finance and Sports Practice with Two New Partners

    Bär & Karrer is pleased to announce that it further strengthens its Financing and Sports practices with new partners Lukas Roesler and Dr. Jan Kleiner, both of whom have worked with the firm previously.
  • Bär & Karrer Advises Novartis and Alcon on the Spin-off of Alcon

    Today, Novartis AG completed the spin-off of the Alcon eye care devices business, and Alcon Inc. debuted as independent publicly traded company. The Alcon shares were successfully listed on the SIX Swiss Exchange Ltd. and the New York Stock Exchange. They are also included in the Swiss Market Index (SMI), which comprises the 20 largest Swiss listed stocks.
  • Bär & Karrer Advises Primeo Energie and CSA Energie-Infrastructure Schweiz in Aquisition from Elét

    Primeo Energie, EOS Holding SA (EOS) and Électricité de France (EDF) have entered into a share purchase agreement relating to the purchase by Primeo Energie and EOS of the 25% interest held by EDF in Alpiq Holding SA. The purchase by Primeo Eergie and EOS will be financed through mandatory exchangeable loan agreements made by CSA Energie-Infrastruktur Schweiz (CSA) as lender, the biggest investment pool for Swiss energy infrastructure with 135 Swiss pension funds acting as investors. At maturity the mandatory exchangeable loan agreements will be converted into shares in Alpiq. Primeo Energie and EOS thereby pave the way for a Swiss shareholder structure of Alpiq.
  • Bär & Karrer Awarded Most Innovative Swiss Law Firm of the Year at the IFLR Europe Awards

    Bär & Karrer was awarded „Most innovative law firm of the year - Switzerland", the national award for Switzerland given in the IFLR European Awards. The most innovative law firm of the year award recognizes Bär & Karrer as the Swiss law firm with the best track record in 2018 giving advice on the most innovative cross-border deals covering all award practice areas. It is already the third prize of this kind in period of six years awarded to Bär & Karrer.
  • Bär & Karrer Advises DSV on Public Exchange Offer for Panalpina

    On 1 April 2019, DSV A/S, Hedehusene, Denmark and Panalpina Welttransport (Holding) AG, Zurich, Switzerland, have entered into an agreement on the terms and conditions of a combination by way of a public exchange offer by DSV for all publicly held registered shares of Panalpina for approximately CHF 4.6 billion. The board of directors of Panalpina has resolved to support the public exchange offer by DSV and to recommend the acceptance of DSV's public exchange offer to its shareholders.
  • Bär & Karrer Advises Lonza on the Entering into a Strategic Joint Venture with Chr. Hansen for Deve

    On 2 April 2019, Lonza, a leading pharma contract manufacturing company, and Chr. Hansen, a leading global bioscience company, announced that they have signed an agreement to establish a 50/50 joint venture to pioneer the live biotherapeutic products (LBPs) industry and position themselves as the leading contract development and manufacturing partner (CDMO) for biotech and pharma customers. The joint venture brings together best-in-class, complementary capabilities and will be the first CDMO globally to provide a full supply chain that offers manufacturing of bacteria strains for therapeutic use. The joint venture will be a 50/50 controlled legal entity that will operate from its headquarters in Basel (CH) and have production facilities in Denmark and Switzerland. A phased investment of approximately EUR 90 million will be deployed over three years to build cGMP-compliant pharma production capabilities. The joint venture will upgrade existing facilities in Hørsholm (DK) and equip new facilities in Basel (CH) to serve pre-clinical to phase II projects. Further facilities for phase III and commercial manufacturing will be developed as the pipeline matures. The joint venture is expected to be largely self-funding after the production set-up has been established.
  • Bär & Karrer Advises Computacenter in the Acquisition of PathWorks

    Computacenter Group, a leading European IT service provider listed on the London Stock Exchange, acquired PathWorks, a well-established hardware reseller in the Swiss market.
  • Bär & Karrer Advises Addtech in the Acquisition of a Majority in Omni Ray

    Addtech Group, a leading Swedish publicly listed technology trading group, acquired a majority stake in Omni Ray AG, a well-established Swiss trading company and service provider for automation solutions, mainly focused on industrial applications, infrastructure, transportation and medical industry. By this transaction, Addtech aims at strengthening its position in the European automation market.